Showing 2601-2610 of 10579 results for "".
DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Red Light vs Blue Light Therapy
https://practicaldermatology.com/series/pdt-in-practice/red-light-vs-blue-light-therapy/26993/Dr. Hamza D. Bhatti, a board-certified dermatologist and dually accredited fellowship-trained Mohs micrographic surgeon and cosmetic dermatologic surgeon, discusses the differences between red light and blue light photodynamic therapy (PDT), the advantages of each, and some off-label uses of PDT.Exosomes 101
https://practicaldermatology.com/conferences/scale-2023/exosomes-101/20192/Exosomes are today's hottest skincare ingredient, and Glynis Ablon, MD, gives viewers the scoop on how and when to use them.DermWireTV: Diversity in Dermatology; Inclusive Beauty Initiatives; Eczema Awareness Month
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-diversity-in-dermatology-inclusive-beauty-initiatives-eczema-awareness-month/20152/La Roche-Posay and the Women's Dermatologic Society have partnered to sponsor a Fellowship in the Department of Dermatology at Howard University's College of Medicine for Underrepresented in medicine medical students. WDS President Mona Gohara, MD shares insights about the need to support DEI in derRadiesse Plus Launches, AAD Convenes, NPF Registry Begins
https://practicaldermatology.com/topics/psoriasis/dermwiretv-radiesse-plus-launches-aad-convenes-npf-registry-begins--epesurag/18939/In this edition of DermWireTV: Merz Aesthetics launches Radiesse Plus with lidocaine for the treatment of facial wrinkles and folds and the National Psoriasis Foundation (NPF) launches new patient registry focused on patient safety. Plus, updates from the annual meeting of the American Academy of DeConnective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.Going Off-Label
https://practicaldermatology.com/conferences/noah-worcester/going-off-label/57063/Francisca Kartono, DO, discusses her presentation, “Practical Pearls: Off-Label Topical and Systemic Strategies that Work,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.A Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituDWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aThe Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.